RT Journal Article SR Electronic T1 An HERV-W ENV transcription in atypical memory B cells linked to COVID-19 evolution and risk for long COVID can express the encoded protein from a ribosome readthrough of mRNA from chromosome X JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.07.03.24309822 DO 10.1101/2024.07.03.24309822 A1 Brunel, Joanna A1 Paganini, Julien A1 Galloux, Melissa A1 Charvet, Benjamin A1 Perron, Hervé YR 2024 UL http://medrxiv.org/content/early/2024/07/03/2024.07.03.24309822.abstract AB The human genome comprises 8% of endogenous retroviruses (HERVs). Though HERVS contribute to physiological functions, copies retained pathogenic potential. The HERV-W ENV protein was shown expressed in patients with worse COVID-19 symptoms and post-COVID syndrome. A significant detection of the mRNA encoding HERV-W ENV from patients with COVID-19 in B cells from RNAseq reads obtained from peripheral blond mononuclear cells. This data stratified with increased COVID-19 symptoms or with post-acute sequelae of COVID-19 (long COVID) after 3 months. The HERV-W ENV-U3R RNA was confirmed to display the best alignment with chromosome X ERVWE2 locus. However, a stop codon precluding its translation was re-addressed after recent understandings of ribosome readthrough mechanisms. Experimental results evidenced that this HERV gene can effectively express a full-length protein in the presence of molecules allowing translation via a readthrough mechanism at the ribosome level. Results not only confirm HERV-W ENV RNA origin in these patients, but show for the first time how a defective HERV copy can be translated into a complete protein when specific factors make it possible at the ribosome level. The present proof of concept now requires further studies to identify the factors involved in this newly understood mechanism, following SARS-CoV-2 exposure.Competing Interest StatementJB, BC, HP are employed by Geneuro Innovation Clinical Protocols https://clinicaltrials.gov/study/NCT04388813 Funding StatementThis study was supported by Geneuro-Innovation SAS, France.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data (publications) on the PRESCO cohort along with refences of ethical approval (also indicated in the present manuscript) and relevant institutions: https://doi.org/10.1016/j.clim.2023.109808 https://doi.org/10.3389/fimmu.2024.1348041 https://doi.org/10.3389/fmed.2023.1227883 Access to RNAseq data set, as indicated in the already published study (https://doi.org/10.1016/j.clim.2023.109808): requests for research use should be directed to: immuneprofiler@verily.comI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors